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Abstract
Purpose: Large-panel genomic tumor testing (GTT) is an emerging technology with great promise but uncertain
clinical value. Previous research has documented variability in academic oncologists’ perceptions and use of GTT, but
little is known about community oncologists’ perceptions of GTT and how perceptions relate to clinicians’ intentions
to use GTT.
Methods: Community oncology physicians (N = 58) participating in a statewide initiative aimed at improving
access to large-panel GTT completed surveys assessing their confidence in using GTT, attitudes regarding the value
of GTT, perceptions of barriers to GTT implementation, and future intentions to use GTTs. Descriptive and multivariable regression analyses were conducted to characterize these perceptions and to explore the relationships between
them.
Results: There was substantial variability in clinicians’ perceptions of GTT. Clinicians generally had moderate confidence in their ability to use GTT, but lower confidence in patients’ ability to understand test results and access targeted treatment. Clinicians had positive attitudes regarding the value of GTT. Clinicians’ future intentions to use GTT
were associated with greater confidence in using GTT and greater perceived barriers to implementing GTT, but not
with attitudes about the value of GTT.
Conclusions: Community oncologists’ perceptions of large-panel genomic tumor testing are variable, and their
future intentions to use GTT are associated with both their confidence in and perceived barriers to its use, but not
with their attitudes towards GTT. More research is needed to understand other factors that determine how oncologists perceive and use GTT in clinical practice.
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Introduction
Genomic tumor testing is an emerging technology that
promises to improve cancer treatment outcomes and has
already enabled successful targeted, “precision” treatments for common and difficult to treat cancers. Prominent examples include erlotinib for EGFR-mutant lung
cancer [1] and vemurafenib for BRAF V600E–mutant
melanoma [2]. Tumor tests for mutations with known
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FDA-approved treatments have quickly become the
standard of care. In recent years, next-generation genome
sequencing technology has enabled the development of
large-panel genomic tumor tests (GTT) that can test and
identify variants in hundreds of genes simultaneously.
However, for many variants identified by large-panel
GTT no current FDA-approved treatments exist, and
the clinical utility of these extended, large-panel testing
is debatable. Nevertheless, GTT is increasingly utilized
in clinical practice. In a 2017 study, 75.6% of oncologists
reported currently using multi-gene GTT to guide treatment decisions [3]. Moreover, as genomic technologies
become less expensive and more accurate [4], utilization
of GTT will likely increase and continue to identify more
genomic variants with uncertain clinical utility [5–7].
These associated uncertainties, along with the increasing dissemination and implementation of GTT in clinical
practice, make it important to understand how oncologists perceive, understand, and actually use this technology. Past research on this topic, however, has been
limited and focused primarily on academic oncologists’
confidence in using GTT. Gray et al. conducted a singleinstitution study of academic medical oncologists, and
found variability in clinicians’ confidence in their knowledge of GTT and their ability to both explain GTT to
patients and to make treatment recommendations based
on genomic information [8]. More recent studies have
yielded mixed findings regarding physicians’ understanding and confidence in their ability to interpret, use, and
discuss the results of GTT with patients [9, 10]. These
mixed findings may reflect differences in the clinical
settings, disease types, and sample populations of these
studies, and raise the need for further research.
More research is also needed to investigate how clinicians’ perceptions of GTT influence their utilization of
these tests. Gray et al. demonstrated that greater confidence in the use of GTT among oncologists was associated with greater anticipated future use of GTT [8]. This
finding is consistent with theories of health behavior,
which theorize that confidence—also referred to as selfefficacy [11]—is a critical determinant of health behavior. However, past studies of GTT have not investigated
the potential influence of other factors thought to be
equally critical, including attitudes regarding the value
of GTT and perceptions of barriers to GTT utilization.
Most research on clinicians’ perceptions of GTT has also
been limited to oncologists practicing at large academic
medical centers (e.g. [8, 9, 12],); clinicians practicing in
community-based settings and rural areas have received
less attention. Emerging evidence suggests, however, that
community oncologists may use GTT less frequently
[13] and that oncologists in rural areas might have more
limited genomic knowledge [14]. More research is thus
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needed to characterize the knowledge, attitudes, and
practices of community oncologists in more rural settings, given that most cancer care in the US is provided in
such settings, and many rural communities have disproportionately high cancer incidence and mortality rates
[15].
The objective of this study was to understand community oncology clinicians’ perceptions of GTT and
how they relate to clinicians’ intentions to use GTT.
We focused on three types of perceptions theoretically
related to GTT use: confidence (self-efficacy) regarding
the use of GTT; attitudes regarding the value of GTT;
and perceived barriers to implementing GTT (e.g. cost,
incidental germline findings). Major health behavior theories hold that behavioral intentions are key precursors
of actual health behaviors [16, 17]. We therefore treated
future intentions to use GTT as a proxy for actual testordering behavior, in order to explore how clinicians’
various perceptions of GTT might be related to their use
of the test.
This study leveraged a unique program, the Maine
Cancer Genomics Initiative (MCGI), designed to overcome the implementation hurdles for large-panel GTT
and precision oncology in rural community settings. The
MCGI is a ten-year (2016–2026), longitudinal, statewide, multi-site initiative aimed at disseminating GTT in
community oncology practices throughout the State of
Maine. The MCGI provides clinicians and their patients
with access to free large-panel GTT as well as clinician education and decision support services, including
genomic tumor boards conducted at multiple practice
sites throughout the state. The MCGI thus provided a
unique opportunity to assess how community-based
oncologists in a predominantly rural state perceive and
use GTT in their practices.

Methods
Study population and design

The study population consisted of actively practicing
oncology physicians in Maine, including hematologists/
oncologists, gynecologic oncologists, and surgical oncologists. Physicians were recruited by the MCGI research
team via in-person site visits, email, and telephone.
Informed consent was obtained from all participants.
Upon joining the MCGI, participating clinicians completed a 30-min baseline survey containing a variety of
measures, including sociodemographic and practice
information, as well as clinicians’ perceptions and future
intentions to use GTT. The survey was self-administered using the online survey platform RedCap Cloud™
between June 2017 and October 2018. The MCGI study
protocol was reviewed and approved by the Western
Institutional Review Board. This study was performed in
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accordance with the ethical standards of the Declaration
of Helsinki or comparable ethical standards.
Measures

The survey questionnaires contained items measuring
the following constructs (see supplemental online Table 1
for exact wording and response options for each survey
question). Questionnaire items were developed by adopting or adapting existing measures in the literature, as
noted below, or developing new items which were piloted
among 3 practicing medical oncologists and further
refined by our team.
Future intentions to use GTT

Clinicians’ intentions to use GTT in the future were
measured by a single question, similar to an item used by
Gray et al. [8], which asked clinicians how many GTTs
they anticipated ordering in the next 12 months.
GTT‑related confidence

Two aspects of clinicians’ confidence in using GTT
were assessed (Fig. 1). First, clinicians’ confidence
or self-efficacy regarding their own ability to use
GTT—which we designate “internal confidence”—
was assessed by three questions, adapted from Gray
et al. [8] The questions asked clinicians to rate their
confidence in their ability to perform three tasks: (1)
interpreting test results; (2) explaining test results to
patients; and (3) using results to inform treatment decisions (Cronbach’s α = 0.877). Second, clinicians’ confidence in the ability of other stakeholders (including
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their practice and patients) to use GTT—which we
designate “external confidence”—was assessed by three
questions asking clinicians to rate their confidence in:
(1) their practice’s ability to implement GTT; (2) their
patients’ ability to understand GTT results; and (3)
their patients’ ability to access targeted therapies and
clinical trials (Cronbach’s α = 0.698). All answers utilized a 5-point Likert scale; 0 = not at all confident to
4 = extremely confident. For each construct, a summary
score was calculated by averaging answers.
Attitudes towards GTT

Clinicians’ attitudes regarding the value of GTT were
assessed by 9 newly developed questions that our team
adapted from attitudinal measures and findings of
prior studies of physician and patient attitudes towards
genomic testing [8, 18, 19]; the same questions were
also asked of patient participants in this study. The
questions asked clinicians to rate their agreement with
4 positively and 5 negatively valenced attitudes (Fig. 2).
The questions began with the statement, “Genomic
tumor testing seems …” which was then paired with
different adjectives (beneficial, harmful*, uncertain,
accurate, trustworthy, unproven*, complicated*, inefficient*, and worthwhile). Ratings utilized a 5-point Likert response scale; 0 = strongly disagree to 4 = strongly
agree. Negative items (identified above with an *) were
reverse coded so that higher values corresponded to
more positive attitudes. A summary score was calculated by averaging answers (Cronbach’s α = 0.698).

Fig. 1 GTT-related Confidence. Black dots represent means. Error bars represent standard error of the mean. Colored dots represent each
participant’s response (position jittered to avoid overplotting). The x-axis labels reflect the response labels on surveys questions: 0 = not at all
confident to 4 = extremely confident (intermediate options were not labelled)
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Fig. 2 Attitudes about the value of GTT. Legend: * = items were reverse coded for aggregated measure and modeling. Black dots represent means.
Error bars represent standard error of the mean. Colored dots represent each participant’s response (position jittered to avoid overplotting). The
x-axis labels reflect the response labels on surveys questions: 0 = strongly disagree to 4 = strongly agree (intermediate options were not labelled)

Perceived barriers to GTT implementation

Clinicians’ perceptions of barriers to implementing GTT
in clinical practice were assessed by 17 questions that
our team developed based on barriers identified in prior
physician studies (Fig. 3) [9]. For each of these items, clinicians were asked to rate their concerns about the use
of GTT in their own practice using a scale of 0 = not at
all concerned to 4 = extremely concerned. A summary
score was calculated by averaging answers (Cronbach’s
α = 0.832).
Data analysis

Descriptive statistics were generated to characterize
the study population. Internal consistency reliability for
the clinician perceptions and attitudes measures was
assessed by calculating Cronbach’s α coefficient. Next, we
fit linear regression models to identify factors associated
with clinicians’ intentions to order GTT in the future.
We first modeled clinician sociodemographic and practice characteristics (gender, years since medical school,
practice size, rurality, and patient volume) alone, then
added behavioral variables (summary scores for confidence, attitudes, and perceived barriers) to the model.
The distribution of the outcome variable (number of
GTTs clinicians intend to order) was right-skewed; therefore, this variable was log-transformed for all models to

meet normality assumptions. A value of 1 was added to
all values to allow for zero values to be log-transformed.
Coefficients reported here were transformed back (exponentiated) to correct for the log-transformation, allowing
the coefficients to be more easily interpreted. All analyses
were conducted using R 3.5.3 [20].

Results
The study team identified 68 oncology physicians in
Maine who were invited to join the Maine Cancer
Genomics Initiative as of October, 2018. One physician was not currently engaged in clinical practice and
was excluded from this analysis. Of the remaining physicians, 58 (87%) joined, consented to participate, and
completed the survey (Table 1). The sample contained
approximately equal number of women (48%) and men
(52%), with an average of 19 years of practice since medical school (range = 4–45 years). The majority of participants were hematology/oncology specialists (84%), and a
substantial proportion (62%) practiced in rural or small
town settings. The average number of newly diagnosed
patients seen for treatment evaluation each month was
21 (range = 5–45).
Clinicians’ perceptions of GTT

Clinicians had a generally high but variable confidence
in their own ability to effectively utilize GTT (Fig. 1),
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Fig. 3 Perceived Barriers to GTT Implementation. Legend: Black dots represent means. Error bars represent standard error of the mean. Colored
dots represent each participant’s response (position jittered to avoid overplotting). The x-axis labels reflect the response labels on surveys questions:
0 = not at all concerned to 4 = extremely concerned (intermediate options were not labelled)

and relatively low confidence in their patients’ ability to
understand GTT results and access targeted therapies
(Fig. 1, Supplemental Table S1).
Despite their varying levels of internal and external
confidence, clinicians generally had positive attitudes
regarding the value of GTT. They showed high levels of
agreement that GTT is beneficial, worthwhile, accurate,
and trustworthy, and high levels of disagreement that
GTT is harmful, causes issues with patient privacy, or is
inefficient. There was variation in their level of agreement
that GTT is uncertain, complicated, and can help most
patients (Fig. 2, Supplemental Table S1).
Perceived barriers to GTT use also varied widely across
clinicians. In general, clinicians were most concerned
about the logistics of implementing GTT and the low
likelihood of identifying clinically actionable results, and
least concerned about the lack of patient interest, litigation, and patient privacy (Fig. 3, Supplemental Table S1).
Factors associated with intentions to use GTT

Clinicians reported intentions to order an average of 26
GTTs in the next 12 months (range 0–150). As noted

above, the distribution was right-skewed with a few clinicians ordering a large number of tests.
Multivariable regression analysis including only clinician sociodemographic characteristics in the model
showed no significant associations with GTT intentions
(Supplemental Table S2). However, in the regression
model including both clinician sociodemographic and
psychological variables, future intentions to use GTT
were significantly higher for clinicians with more practice experience (greater years since medical school):
b = 1.04; 95% CI 1.01, 1.07; p = 0.020 (Table 2). Future
intentions to use GTT were also significantly associated
with greater internal confidence (i.e., their own ability
to utilize GTT) (b = 2.07; 95% CI 1.24, 3.48; p = 0.007;
Table 2), and with greater perceived barriers (b = 1.88;
95% CI 1.07, 3.32; p = 0.030). Future intentions were
not significantly associated with attitudes regarding the
value of GTT or external confidence (i.e., patients ability to understand results or access treatment and their
practice’s ability to implement GTT) though there was
a non-significant trend for both associations (Table 2).
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Table 1 Physician Demographic and Practice Variables
N (%)
Gender
Female

26 (48%)

Male

28 (52%)

Missing

4

Rurality
Rural

18 (34%)

Small town

15 (28%)

Suburban

12 (23%)

Urban

8 (15%)

Missing

5

Specialty
Hematology/Oncology

48 (84%)

Surgical Oncology

4 (7.0%)

Gynecologic Oncology

2 (3.5%)

No Specialty Identified

3 (5.3%)

Missing

1

Practice Size (Number of oncology physicians)
1–4

23 (45%)

5–9

12 (24%)

10+

16 (31%)

Missing

7

Years since medical school
1–9

8 (15%)

10–19

24 (44%)

20–29

13 (24%)

30+

9 (17%)

Missing

4

Mean (SD)
Average number of newly diagnosed patients each
montha
Percentage of time spent on direct patient careb

21 (10)
88% (13)

Patient Insurance Status (percent of caseload):
 Uninsuredc

12% (9)

 Medicaidd

22% (13)

Commercially Insurede

27% (10)

 Medicaref

44% (13)
a

b

c

d

e

f

Number of responses: n = 52; n = 52; n = 47; n = 47; n = 48; n = 47

Discussion
This study examined community-based oncology physicians’ perceptions of GTT and how those perceptions
relate to their intentions to use GTT in clinical practice. To our knowledge, this is the first study to include
oncologists practicing in rural community settings, and
to assess not only oncologists’ confidence in using GTT
but also their attitudes towards GTT use, and their
perceived barriers, and to examine how these factors
relate to their future use of GTT. The study yielded several findings that have important implications for the

implementation of GTT in community oncology practice settings.
First, we found that more years since medical school
was associated with greater intentions to order GTTs.
This finding contrasts a nationally representative study
which suggested that oncologists were more likely to
order GTTs if they were younger than 50 years old [3].
This discrepancy may be due to differences in measures
(e.g., dichotomized age vs years since medical school)
and study populations. Interestingly, although a small
study in Canada demonstrated rural-urban differences in
genomic expertise and knowledge [14], our study showed
no effect of rurality; however, our entire sample was
arguably more rural than populations examined in other
studies.
Consistent with previous research in academic physician populations [8, 12], we found wide variation in
community-based oncologists’ confidence in using GTT.
Clinicians in our study reported generally high levels of
confidence in their own ability to use GTT, and lower
confidence in patients’ ability to understand results and
access targeted therapy. Although our goal was not to
directly compare levels of confidence to those observed
in other studies, when we rescaled rating of confidence
to a shared 0–1 scale (0 = low confidence to 1 = high confidence), clinicians in our study had very similar confidence in their own abilities (Mean = .655) compared to
clinicians in Gray et al. (Mean = .667; see supplemental
online materials for additional details) [8]. Also consistent with findings from Gray et al. [8] and as predicted
by theories of health behavior [16, 17], we found that
greater clinician confidence in their ability to use GTT
(i.e., self-efficacy) was associated with greater future
intentions to use GTT. Together, these findings suggest
that the successful dissemination and implementation of
GTT in community oncology settings might depend on
increasing oncology clinicians’ confidence in using GTT,
in addition to ensuring that patients are able to benefit
from GTT. Clinicians’ internal confidence in GTT might
be increased through various educational interventions,
including genomic tumor boards, while their external
confidence might be increased through the provision of
patient-focused decision support or navigation services.
We also found that community-based oncologists had
generally positive attitudes regarding the value of GTT.
In health behavior theories, attitudes are important
determinants of behavior [21–23]. Interestingly, however, in our study attitudes were not associated with
clinicians’ intentions to order GTT. More research is
needed to explain this lack of association, but one possibility is that other variables—such as local practice
norms or the availability of GTT—may have greater
influence on clinicians’ intentions and actual use of
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Table 2 Predictors of Intentions to use Genomic Tumor Tests in the Next 12 Months
Factor1

95% CI2

Female

–

–

Male

1.72

0.98, 3.03

0.061

Years since medical school

1.04

1.01, 1.07

0.020

Practice Size (Number of oncology physicians)

0.99

0.92, 1.07

0.8

Rural practice location

0.66

0.34, 1.26

0.2

Average number of newly diagnosed patients each month

1.01

0.98, 1.05

0.3

p-value

Demographic Variables
Gender

Psychological Variables
Attitudes Summary Score

1.79

0.87, 3.68

0.11

Confidence Summary Score - Internal

2.07

1.24, 3.48

0.007

Confidence Summary Score - External

0.64

0.38, 1.08

0.094

Barriers Summary Score

1.88

1.07, 3.32

0.030

1

Factor = exponetiated regression coefficient; every unit increase in the predictor variable is associated with a multiplicative effect of the coefficient on the number
of GTT orders in the next 12 months

2

CI Confidence Interval

N = 48 due to some participants were missing data (see Table 1)

GTT. The relative lack of variation in clinician attitudes
towards GTT in our sample may also have contributed
to the observed lack of association between GTT attitudes and intentions.
Our study also found wide variation in communitybased oncologists’ perceptions of barriers to utilizing GTT. Overall, the barriers of greatest concern were
lack of insurance coverage and low probability of finding actionable results. It is interesting that lack of insurance coverage was considered a barrier of concern since
the MCGI initiative offered free testing. Most likely, this
concern existed before MCGI, and may return after the
initiative ends. The barriers of least concern were lack
of patient and colleague interest. Variants of unknown
significance and managing patient expectations were
barriers of moderate concern, mirroring findings using
qualitative interviews [9]. Clinicians in our study also
perceived incidental identification of germline mutations as a barrier of moderate concern, similar to a study
of patients [24]. Paradoxically, we found greater overall level of clinician concern about barriers to GTT was
associated with greater intentions to use GTT. A possible explanation of this finding is that the level of concern
about barriers to GTT may simply be a marker or result
of greater use of GTT, rather than a cause. This finding
raises the need for further research studies, using longitudinal or experimental designs, that can establish the
causal direction of these and other relationships. In any
case, future efforts to disseminate and implement GTT
in community oncology practice will need to address the
perceived and real barriers to its use.

Limitations, strengths, and future directions

This study had several limitations that qualify the findings and call for further research. First, the study was
conducted as part of a broader implementation initiative
that offered free GTT along with educational support
(e.g. genomic tumor boards). Both of these factors may
have influenced clinicians’ perceptions and use of GTTs,
and may limit the generalizability of our findings to other
practice settings. Furthermore, our study sample was
relatively small and limited to a single state. For instance,
we lacked power to explicitly test for differences between
rural and urban practices, an important question that
will need to be addressed by future studies. Additionally, future work should test whether other variables, like
the proportion of time clinicians spend on patient care,
influence test ordering. Nevertheless, to our knowledge
the current study is the first of its kind to enroll nearly all
practicing community oncology physicians in a predominantly rural state, and was thus regionally representative.
The current study was cross-sectional in nature; therefore, we cannot draw inferences about the causal directions of the observed associations. However, our study
generates hypotheses that can be tested in more definitive
future studies, which we will be conducting in the future
using longitudinal data that is currently being collected.
The current study also used intentions to order GTT as a
proxy for actual GTT use; our future studies will address
this limitation as well, by examining actual test-ordering
behavior. Finally, because GTT is a relatively new intervention in cancer care, many of our study measures were
newly developed, and further research is needed to assess
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their reliability and validity. Despite these limitations, our
study provides important new evidence on communitybased oncology physicians’ perceptions and practices
regarding GTT, and the relationships between them.

Availability of data and materials
The dataset from the current study is not publicly available because the small
sample of clinicians might be re-identifiable. A limited version of the dataset is
available from the corresponding author on request.

Conclusions
Community oncologists’ perceptions of GTT vary widely,
and their confidence in their ability to use GTT is associated with their future intentions to order it. A better understanding of these factors will enable clinicians,
researchers, and health policy makers to address barriers
to disseminating and implementing GTT in community
oncology practice and to promote its appropriate use.
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